AFM
CRMD icon

Anson Funds Management’s CorMedix CRMD Stock Holding History

Anson Funds Management’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-725,000
Closed -$8.93M – 126
2025
Q2 		$8.93M Buy
+725,000
New +$8M 1.29% 20
2024
Q1 		– Sell
-199,000
Closed -$748K – 167
2023
Q4 		$748K Buy
+199,000
New +$685K 0.09% 111

Other funds holding CRMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Anson Funds Management's CRMD Position: Q3 2025 in Review

Anson Funds Management sold out of CorMedix (CRMD) in Q3 2025, closing a stake of 725,000 shares — an estimated $8.93M sold.

Anson Funds Management first reported a position in CRMD in Q4 2023 and held it in 2 quarters. The position peaked at $8.93M in Q2 2025. 190 funds tracked by Wall St. Rank hold CRMD as of Q3 2025.

  • Anson Funds Management reported no remaining CorMedix position as of Q3 2025 after selling out during the quarter.
  • Anson Funds Management sold 725,000 CorMedix shares in Q3 2025, an estimated $8.93M.
  • Anson Funds Management first reported a position in CorMedix in Q4 2023 and held it in 2 quarters.
  • Anson Funds Management's CorMedix position peaked at $8.93M in Q2 2025.
  • 190 funds tracked by Wall St. Rank held CorMedix as of Q3 2025.

Based on Anson Funds Management's 13F filing for Q3 2025, filed 14 Nov 2025.